CD147 expression is associated with poor overall survival in chemotherapy treated triple-negative breast cancer
Publication in refereed journal


Times Cited
Altmetrics Information
.

Other information
AbstractAIMS:
In breast cancer models, the functional roles of CD147 in proliferation, invasion and treatment resistance have been widely reported. However, there are only a few studies examining the clinicopathological correlation and prognostic relevance of CD147 in breast cancer, especially in relation to breast cancer molecular subtypes.

METHODS:
In this study, we analysed CD147 expression in a large cohort of breast cancers, correlating with clinicopathological features and the expression of a comprehensive panel of biomarkers in triple-negative breast cancer (TNBC) and non-TNBC subsets. Its relationship with patients' survival was also analysed.

RESULTS:
CD147 was expressed in 11.9%(140/1174) of all cases and in 23.8% (40/168) of TNBC. The expression was associated with tumour histological subtypes (p=0.01) and most commonly seen in carcinoma with medullary features (26.0%). CD147 expression correlated with high tumour grade, presence of necrosis and basal-like breast cancer (BLBC) subtype, high Ki67 and expression of some other basal markers and stem-like markers. CD147 expression was also associated with poor overall survival in chemotherapy treated patients with TNBC.

CONCLUSIONS:
CD147 is a putative marker in identifying TNBC or BLBC, and may be useful as a prognosis indicator for patients with TNBC or BLBC post chemotherapy.
All Author(s) ListMing Liu, Julia Y S Tsang, Michelle Lee, Yun-Bi Ni, Siu-Ki Chan, Sai-Yin Cheung, Jintao Hu, Hong Hu, Gary M K Tse
Journal nameJournal of Clinical Pathology
Year2018
Month11
Volume Number71
Issue Number11
Pages1007 - 1014
ISSN0021-9746
LanguagesEnglish-United Kingdom

Last updated on 2021-01-12 at 23:33